Precigen, Inc. (PGEN)
NASDAQ:PGEN
Want to see PGEN full AI Analyst Report?
Earnings Data
Report Date
Aug 10, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
>-0.01Last Year’s EPS
-0.09Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum for PAPZIMEOS with a rapid revenue ramp, broad payer coverage, expert endorsement, and promising clinical durability data — all signaling an impactful product launch. The company also faces near-term operational challenges including elevated quarter cash burn, increased SG&A tied to commercialization, timing of cash collections, and limited disclosure of granular conversion metrics. Management expects cash consumption to moderate in Q2 and projects runway to cash-flow breakeven by end-2026, which, together with the strong launch indicators, supports a constructive outlook.Company Guidance
Strong Commercial Launch and Revenue Acceleration
PAPZIMEOS net product revenue for Q1 2026 (first full quarter) was $21.6 million, up from $3.4 million in Q4 2025 (≈+535% quarter-over-quarter), contributing to total revenue of $23.3 million for the quarter.
Broad Payer Coverage and Patient Access
Estimated total lives covered through commercial, Medicare and Medicaid is ~297 million, representing more than 90% of insured U.S. lives, supporting broad patient access.
Patient Hub Growth and Community Penetration
Approximately 400 patients registered in the Precigen patient hub as of the call, with 25% (≈100 patients) coming from community settings, indicating reach beyond major academic centers.
Regulatory and Coding Milestones
Permanent J-code assigned on April 1, 2026 which will simplify claims processing and is expected to facilitate broader access and faster reimbursement.
Clinical Durability and Upcoming Scientific Data
Management highlighted durable responses with a median follow-up of three years from clinical data; updated durability data is planned to be presented at ASCO next month, supporting clinical adoption and label strength.
Operational Achievements and Expert Endorsement
First commercial therapeutic launch in RRP history with a landmark expert position paper (RRP Foundation; 16 U.S. physicians) recommending PAPZIMEOS as preferred first-line therapy, reinforcing physician adoption.
Controlled Operating Loss and Net Loss
Operating loss for the quarter was $6.0 million (characterized as 'only $6 million' by management) and net loss was $7.9 million ($0.02 per basic and diluted share), reflecting significant revenue offsetting operating costs in the launch quarter.
Funding Runway Outlook
Cash, cash equivalents and investments totaled $56.7 million at quarter-end. Management expects cash, plus collection of PAPZIMEOS receivables, to fund operations through reaching cash-flow breakeven by the end of 2026 and currently does not expect the need to access capital markets.
Pipeline Progress and Future Indications
Pediatric trial for PAPZIMEOS planned to initiate in Q4 2026; PRGN-2009 (AdenoVerse platform) advancing in multiple Phase II trials in combination with pembrolizumab for HPV-16/18-driven cancers with updates expected later in the year.
PGEN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
PGEN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2026 | $4.15 | $4.60 | +10.84% |
Mar 25, 2026 | $3.10 | $3.89 | +25.48% |
Nov 13, 2025 | $3.86 | $4.85 | +25.65% |
Aug 12, 2025 | $1.74 | $1.80 | +3.45% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Precigen, Inc. (PGEN) report earnings?
Precigen, Inc. (PGEN) is schdueled to report earning on Aug 10, 2026, After Close (Confirmed).
What is Precigen, Inc. (PGEN) earnings time?
Precigen, Inc. (PGEN) earnings time is at Aug 10, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PGEN EPS forecast?
PGEN EPS forecast for the fiscal quarter 2026 (Q2) is >-0.01.